Get the Weekly Intelligence Brief — top committee picks every Sunday.

ANIP vs BFLY

ANI Pharmaceuticals, Inc. vs Butterfly Network, Inc. — AI-powered side-by-side comparison
ANIP
ANI Pharmaceuticals, Inc.
60
Insufficient Data
VS
BFLY
Butterfly Network, Inc.
67
Buy
MetricANIPBFLY
AI Score 60 67
Price $74.51 $9.36
P/E Ratio 15.43× -32.38×
ROE 14.5% -39.3%
Revenue Growth YoY
Gross Margin 65.2% 51.1%
Debt / Equity 0.55× 0.10×
Dividend Yield 0.0% 0.0%
RSI (14) 31.0 66.4
Beta 0.464 2.084
Expected Upside

AI Committee View

Current Innellis committee reasoning for ANIP versus BFLY.
BFLY leads by 7 points.

BFLY scores 67/100 (Buy) versus ANIP at 60/100 (Insufficient Data).

ANIP Committee View
67% agreement
3 analysts

Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull Case
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Price trading below the lower Bollinger Band -- stretched to the downside — Technical
BFLY Committee View
67% agreement
6 analysts

The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.

Bull Case
  • Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • ROE of only -38.4% -- cheap may mean cheap for a reason — Value
  • Bollinger bandwidth of 52.6% signals elevated volatility — Risk
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ANIP Full Analysis BFLY Full Analysis